转移性去势抵抗性前列腺癌患者前列腺特异性膜抗原低表达被认为不适合177Lu标记PSMA放射配体治疗后的不良结局
在一项前瞻性试验中,对转移性去势抵抗性前列腺癌患者进行68Ga-PSMA-11和18F-FDG PET/CT筛选,16例(24%)因PSMA低表达(n=8)或FDG阳性PSMA阴性不一致病变(n=8)未入组。这些患者中位OS为2.5个月(95%CI 1.7-5.0),15例死亡,提示预后不良。
要点
- 筛选患者中24%因PSMA低表达或FDG不一致未入组。
- 未入组患者中位OS仅2.5个月(95%CI 1.7-5.0)。
- 所有患者多线治疗后进展,预后极差。
核心结论
- 常规治疗后进展的mCRPC患者中,PSMA低表达或FDG阳性PSMA阴性不一致病变提示预后不良和生存期短。
研究设计与样本
- 前瞻性试验中,对接受68Ga-PSMA-11和18F-FDG PET/CT筛选的患者进行观察,分析因PSMA低表达或FDG阳性PSMA阴性不一致病变未入组者的结局。
主要发现
- 16例(24%)未入组,其中PSMA低表达8例,FDG阳性PSMA阴性不一致病变8例。
- 中位前列腺特异性抗原倍增时间为2.1个月。
- 11例Gleason评分≥8分。
- 所有患者既往多西他赛治疗后进展,44%卡巴他赛治疗后进展,94%阿比特龙和/或恩扎卢胺治疗后进展。
- 9例接受后续全身抗肿瘤治疗;15例死亡,中位OS为2.5个月(95%CI 1.7-5.0)。
局限性
- 定义PSMA低表达的影像学阈值存在不确定性。
- 放射性核素治疗可能改善该队列生存期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prostate-specific membrane antigen (PSMA) is overexpressed in metastatic castration-resistant prostate cancer (mCRPC) and represents a target for imaging and therapy. We undertook a prospective trial of 177Lu-PSMA-617 radioligand therapy in men with high PSMA expression who progressed after standard therapies. OBJECTIVE: To determine outcomes for men screened for the trial but not treated because of low PSMA expression. DESIGN, SETTING, AND PARTICIPANTS: Patients screened with 68Ga-PSMA-11 and 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography in a prospective trial. Patients ineligible for enrolment with low PSMA expression or FDG-positive PSMA-negative (discordant FDG-avid) disease were assessed. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Subsequent treatments received were recorded. Kaplan-Meier analysis was used to determine overall survival from date of screening. RESULTS AND LIMITATIONS: Sixteen patients (24%) had low PSMA expression (n=8) or discordant FDG-avid disease (n=8). The median prostate-specific antigen doubling-time was 2.1mo. Eleven patients had Gleason ≥8 disease. All patients had previously progressed after docetaxel, 44% after cabazitaxel, and 94% after abiraterone and/or enzalutamide. Nine patients had subsequent systemic antitumour treatment. Fifteen patients died, with median OS of 2.5mo (95% confidence interval 1.7-5.0). Study limitations include uncertainty for imaging thresholds that define low PSMA expression. It is also possible that theranostic therapy could have improved survival in this cohort. CONCLUSIONS: Low PSMA expression or discordant FDG-avid disease in patients with mCRPC who progress after conventional therapies identifies a group with poor prognosis and short survival. PATIENT SUMMARY: The 177Lu-PSMA-617 radioligand may be an effective therapy for patients with advanced prostate cancer who progress after standard therapies. In this report we looked at outcomes for patients who were not eligible for this novel therapy on the basis of low prostate-specific membrane antigen uptake on screening positron emission tomography scans. We found that their outcomes were poor, with short survival.
引用
- Thang SP, Violet J, Sandhu S, et al. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy. Eur Urol Oncol. 2018. PMID: 31412006. doi:10.1016/j.euo.2018.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。